{"entity":{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","aka":["Jiangsu Aosaikang Pharmaceutical","ASK Pharm","奥赛康药业"],"tldr":"Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours.","summary":"Aosaikang Pharmaceutical is a research-driven pharmaceutical manufacturer listed in Shenzhen that develops, produces and sells active ingredients and finished medicines in gastroenterology, oncology, anti-infectives and chronic disease. Its site cites China's first injectable proton pump inhibitor as a flagship product and lists clinical-stage innovative candidates including molecular glue degraders. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT04632108 (phase 1/2, A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor...), NCT04143607 (phase 3, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metast...) and NCT07109531 (phase 3, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Loc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ask-pharm.com/"},{"label":"ClinicalTrials.gov: trials led by Aosaikang Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Jiangsu%20Aosaikang%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["limertinib","carboplatin","cisplatin","pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04632108","nct04143607","nct07109531"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Nanjing","country":"CN","companyType":"pharma","website":"https://www.ask-pharm.com/","ticker":"SZSE:002755","founded":2003,"stage":"public","investors":[],"funding":[]},"route":"/companies/aosaikang-pharmaceutical/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"trial":[{"id":"nct04632108","kind":"trial","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04632108/"},{"id":"nct04143607","kind":"trial","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","route":"/trials/nct04143607/"},{"id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/"}]}}